Evidence map›Paper›PMID 27241473›Full record

ArticleNature communications2016

Rational design of a protein that binds integrin αvβ3 outside the ligand binding site.

Ravi Chakra Turaga, Lu Yin, Jenny J Yang, Hsiauwei Lee, Ivaylo Ivanov, Chunli Yan, Hua Yang, Hans E Grossniklaus, Siming Wang, Cheng Ma and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Evaluation of an Integrin αNuclear medicine and molecular imaging · 2023
    Article
  16. Article
  17. Review
  18. Hepatic Stellate Cell Targeting Using Peptide-Modified Biologicals.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Ravi Chakra TuragaDepartment of Biology, Georgia State University, Atlanta, Georgia 30303, USA.ORCID 0000-0001-9075-7645
Lu YinDepartment of Biology, Georgia State University, Atlanta, Georgia 30303, USA.
Jenny J YangDepartment of Chemistry, Georgia State University, Atlanta, Georgia 30303, USA.
Hsiauwei LeeDepartment of Chemistry, Georgia State University, Atlanta, Georgia 30303, USA.
Ivaylo IvanovDepartment of Chemistry, Georgia State University, Atlanta, Georgia 30303, USA.
Chunli YanDepartment of Chemistry, Georgia State University, Atlanta, Georgia 30303, USA.
Hua YangDepartment of Ophthalmology, Eye Center, Emory University, Atlanta, Georgia 30322, USA.
Hans E GrossniklausDepartment of Ophthalmology, Eye Center, Emory University, Atlanta, Georgia 30322, USA.
Siming WangDepartment of Chemistry, Georgia State University, Atlanta, Georgia 30303, USA.
Cheng MaDepartment of Chemistry, Georgia State University, Atlanta, Georgia 30303, USA.
Li SunCenter for Diagnostics and Therapeutics, Amoytop Biotech Inc., Xiamen 361028, China.
Zhi-Ren LiuDepartment of Biology, Georgia State University, Atlanta, Georgia 30303, USA.
Georgia State University · USEmory University · USDian Diagnostics (China) · CN

Funding

P30-Core Grant for Vision Research Core CP30EY006360 · NEI · EMORY UNIVERSITY · PI BOATRIGHT, JEFFREY H · 1986 to 2025
$15.3M
Designing Magnetic Resonance Protein-based Contrast Agents with High RelaxivityR01EB007268 · NIBIB · GEORGIA STATE UNIVERSITY · PI YANG, JENNY J. · 2007 to 2015
$3.1M
GAP JUNCTIONS AND IONIC CURRENTS IN DEVELOPING HEARTR01HL042220 · NHLBI · UPSTATE MEDICAL UNIVERSITY · PI VEENSTRA, RICHARD DAVID, YANG, JENNY J. · 1988 to 2013
$3.1M
P68 and Ca-calmodulin interaction in cell migrationR01CA118113 · NCI · GEORGIA STATE UNIVERSITY · PI LIU, ZHI-REN · 2007 to 2018
$2.3M
Development of anti-angiogenesis therapy targeting integrinR01CA175112 · NCI · GEORGIA STATE UNIVERSITY · PI LIU, ZHI-REN · 2014 to 2018
$2.0M
Integrative modeling of PCNA assemblies engaged in genome duplication and repairR01GM110387 · NIGMS · GEORGIA STATE UNIVERSITY · PI IVANOV, IVAYLO NIKOLAEV · 2015 to 2019
$1.7M
NCI NIH HHS R01 CA118113NCI NIH HHS R01 CA175112NEI NIH HHS P30 EY006360NHLBI NIH HHS R01 HL042220NIBIB NIH HHS R01 EB007268NIGMS NIH HHS R01 GM110387
6 · The paper itself

Abstract

Integrin αvβ3 expression is altered in various diseases and has been proposed as a drug target. Here we use a rational design approach to develop a therapeutic protein, which we call ProAgio, that binds to integrin αvβ3 outside the classical ligand-binding site. We show ProAgio induces apoptosis of integrin αvβ3-expressing cells by recruiting and activating caspase 8 to the cytoplasmic domain of integrin αvβ3. ProAgio also has anti-angiogenic activity and strongly inhibits growth of tumour xenografts, but does not affect the established vasculature. Toxicity analyses demonstrate that ProAgio is not toxic to mice. Our study reports a new integrin-targeting agent with a unique mechanism of action, and provides a template for the development of integrin-targeting therapeutics.

Indexed as

Drug DesignAmino Acid SequenceAngiogenesis InhibitorsAnimalsApoptosisBinding SitesCell LineFemaleHumansIntegrin alphaVbeta3LigandsMaleMiceMice, Inbred BALB CMice, NudeMolecular Docking SimulationAngiogenesis InhibitorsIntegrin alphaVbeta3Ligands

Identifiers

PMID27241473
PMCPMC4895024
OpenAlexW2461667278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.